Senhwa Biosciences (6492)

Currency in TWD
35.70
-0.50(-1.38%)
Closed·
6492 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected today
6492 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
35.7036.50
52 wk Range
28.4558.80
Key Statistics
Bid/Ask
189.00 / 189.50
Prev. Close
41.55
Open
36.5
Day's Range
35.7-36.5
52 wk Range
28.45-58.8
Volume
79.47K
Average Volume (3m)
237.2K
1-Year Change
-26.12%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6492 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Liquid assets exceed short term obligations

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Senhwa Biosciences Company Profile

Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidnarulex and talazoparib in patients with metastatic castration resistant prostate cancer. It is also developing CX-4945-CCA that is in phase I/II clinical trial in combination with gemcitabine for the treatment of patients with cholangiocarcinoma; CX-4945-BCC, which is in phase I, multi-center, open-label, treatment duration increment, expansion, safety, and pharmacodynamic study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma; and CX-4945-MB, a pediatric brain tumor consortium that is in phase I/II and surgical study of CX-4945 in patients with recurrent SHH medulloblastoma. In addition, the company develops CX-4945-AV06, a phase II, double blind randomized, controlled study to evaluate the safety and efficacy of CX-4945 in hospitalized adults with COVID-19. Senhwa Biosciences, Inc. was incorporated in 2012 and is based in New Taipei City, Taiwan.

Compare 6492 to Peers and Sector

Metrics to compare
6492
Peers
Sector
Relationship
P/E Ratio
−11.1x−24.4x−0.5x
PEG Ratio
5.590.020.00
Price/Book
3.3x2.7x2.6x
Price / LTM Sales
3,228.5x30.1x3.3x
Upside (Analyst Target)
-0.0%43.5%
Fair Value Upside
Unlock−17.4%6.9%Unlock

Earnings

Latest Release
May 30, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

6492 Income Statement

FAQ

What Stock Exchange Does Senhwa Biosciences Trade On?

Senhwa Biosciences is listed and trades on the Taipei Exchange stock exchange.

What Is the Stock Symbol for Senhwa Biosciences?

The stock symbol for Senhwa Biosciences is "6492."

What Is the Senhwa Biosciences Market Cap?

As of today, Senhwa Biosciences market cap is 3.23B.

What Is Senhwa Biosciences's Earnings Per Share (TTM)?

The Senhwa Biosciences EPS (TTM) is -3.27.

When Is the Next Senhwa Biosciences Earnings Date?

Senhwa Biosciences will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is 6492 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Senhwa Biosciences Stock Split?

Senhwa Biosciences has split 1 times.

How Many Employees Does Senhwa Biosciences Have?

Senhwa Biosciences has 0 employees.

What is the current trading status of Senhwa Biosciences (6492)?

As of 07 Aug 2025, Senhwa Biosciences (6492) is trading at a price of 35.70, with a previous close of 41.55. The stock has fluctuated within a day range of 35.70 to 36.50, while its 52-week range spans from 28.45 to 58.80.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.